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ABSTRACT  
Incidences of pancreatic cancer worldwide have been known to be increased. It is the fifth leading 
cause of death in United State of America. Seventy percent occurs in the head of the pancreas. Major risk 
factors are related to age, black race, smokers, high-fat diet, chronic pancreatitis, diabetes mellitus and 
alcohol consumption. Some clinical symptoms such as jaundice, abdominal pain, unexplained weight loss or 
ascites can occur early or even late in the course of disease.  
Diagnosing pancreatic cancer sometimes can be difficult, regarding to discrepancy between clinical 
symptoms and radiological findings. It is important to take good history of the patient, thorough 
examination, and combine several modalities in diagnosing tumor of pancreatic head.  
In this case report, a 54 year-old female, came to the hospital with abdominal swelling and jaundice. 
Physical examination revealed liver and spleen enlargement and edema on both lower extremities. The 
laboratory result showed increment in Carcinoembryonic Antigen (CEA) and carbohydrate antigen 19-9 
(CA19-9) level, without marked increase in bilirubin level. Dilatation of the pancreatic duct was found in 
this patient, without any sign of bile stone. Endoscopic Retrograde Cholangiopancreatography (ERCP) in 
this patient was failed to have significant result.  
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INTRODUCTION 
Pancreatic cancer is a cancer which mostly arises  
from the ductal epithelial cells (90%) and most  
frequently occurs as adenocarcinoma (75%). Until now,  
there is no effective screening test for the pancreatic  
cancer. Most cases, i.e. almost 70% occur within  
the head of the pancreas (caput of pancreas) and it  
commonly causes obstruction due to its invasion into  
common bile duct and pancreas duct resulting in  
clinical jaundice. 
The early symptoms of the pancreatic cancer are  
not specific and often ignored. These initial symptoms 
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last more than 2 months prior to the cancer diagnosis.1 
Patients usually experience clinical symptoms when  
the tumor has invaded beyond the pancreas.  
The clinical symptoms include abdominal pain and  
unexplainable weight loss. Painless jaundice occurs in  
10-20% of patients with cancer of pancreatic head.  
Important clinical manifestations but rarely occur are  
pancreatitis, migratory thrombophlebitis, hypoglycemia,  
elevated calcium level, endocarditis and diabetes 
mellitus.1,3,7 
Incidence of exocrine pancreatic cancer is 80-90%  
of all pancreatic tumor. The worldwide incidence of  
pancreatic cancer is 8-12 cases per 100,000 male  
patients, and 1.5- 7 case per 100,000 female patients.  
The male-to-female ratio is 2:1. This cancer is the fifth  
leading cause of death in United States of America.  
The median age approximately is 60-80 years  
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(in 80 cases). The risks increase in smoker, black race, 
high-fat diet, alcohol, elderly, diabetes mellitus, and 
chronic pancreatitis.1 Pathogenesis of the pancreatic 
cancer is assumed due to accumulation of various gene 
mutations. The common gene mutations for 
pancreatic cancer include K-ras genes, CK-19, 
depletions and mutations of tumor suppressor genes, 
such p53, p16, DPC4 and BRCA2.2 
In simple words, the diagnostic approach for  
carcinoma of pancreatic head includes complete  
history taking, thorough physical examination, and  
workup studies such as tumor markers and imaging  
studies. Diagnosis frequently deals with difficulties since  
the symptoms usually arise after the tumor has reached  
advance stage of disease. Moreover, several  
modalities that utilized separately frequently fail to  
detect carcinoma of pancreatic head. Such problems  
result in delayed diagnosis. 
 
CASE 
A 54 year-old female patient was hospitalized with  
a main symptom of abdominal swelling since three days  
before admission. The symptom was accompanied with  
sensation of full-stomach, nausea, and edema on both  
lower extremities. There was no vomiting and  
dyspnea, either during activity or at rest. After 2-week  
hospitalization, the patient experienced subtle  
intermittent fever and accompanied by dry cough,  
lightening stools and darkening urine resembling to  
tea-colored solution. Four months later, the patient  
noticed yellow colored eyes and skin, and sometimes  
together with epigastric pain. Previously, the patient  
had come to other hospital and had undergone an  
ultrasonography examination, which revealed stone of  
her bile duct. 
The patient had suffered hypertension for a year 
but she had irregular visit to local primary health care 
center. She denied any past medical history of 
diabetes mellitus, blood transfusion, and jaundice. She 
had not had smoking habits or alcoholic consumption. 
She usually had high-fat diet and oily food. There was 
no history of malignancy in her family. 
The first physical examination revealed full alert  
consciousness with moderate illness. The blood  
pressure was 160/80 mmHg, pulse was regular with  
the rate of 90 x/minute, body temperature 37oC, and  
respiratory rate 22 x/minute. She had active rest  
position and malnutrition. No deformity on face and  
head with normal face expression. Her hair was mostly  
strong and grey with no hair loss. The eye examination  
revealed pale conjunctiva and jaundice of sclera. There  
was no lymph node enlargement on the neck region.  
The chest examination revealed vesicular breath sound  
and rhonchi on the left lung base, and no wheezing.  
The left margin of the heart was extend about 1 finger 
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to the lateral of left mid-clavicle line, there was normal 
heart sounds (normal S1 - S2), no murmur or gallop. 
Abdomen was distended, loose, and there was 
tenderness on palpation at the right upper quadrant of 
the abdomen. The liver was detected on palpation at 3 
fingers side below the arcus costae, and 3 fingers 
below the processus xyphoideus. Lien was detected 
on palpation with lien enlargement until the line of 
Shuffner 2. There was shifting dullness and normal 
bowel sound. Extremities were warm and there was 
pitting edema on pre tibia region. 
A preliminary laboratory data showed following  
results: hemoglobin 8.2 g/dL, hematocryt 26.4%,  
leukocytes 11,600 cells/uL, and platelets 186,000 cells/  
uL, alanine aminotransferase (ALT) 141 U/L,  
aspartate aminotransferase (AST) 38 U/L, with  
albumin 2.0 g/dL and globulin 4.4 g/dL. The renal  
function was within normal limits, i.e. ureum 30 mg/dL  
and creatinine 1.1 mg/dL. The results also revealed  
direct bilirubin level of 6.1 mg/dL and indirect bilirubin  
level of 3.0 mg/dL. The blood glucose test revealed  
normal result (88 g/dL) and the electrolyte level,  
i.e. sodium level was 138 mEq/L, potassium level was  
3.7 mEq/L, and chloride level was 107 mEq/L.  
The urine test demonstrated positive bilirubin result,  
while other results were within the normal range  
 Based on such results, the initial problem of this  
patient were liver cirrhosis, jaundice, anemia,  
hypertension grade II, and pneumonia. The diagnosis  
of liver cirrhosis was established based on physical  
findings of abdominal distention since 3 days before  
admission, edema on both lower extremities. Physical  
examination resulted hepatomegaly, ascites, and  
pitting edema on pre tibia region. There albumin-to- 
globulin ratio was inversed and there was increment  
of aminotransferase enzymes. It was considered as  
liver cirrhosis with differential diagnosis of bile  
cirrhosis. Early diagnosis approaches were prepared  
including seromarker test for hepatitis (HbsAg, anti  
HCV), abdominal ultrasonography (USG) and  
endoscopy. As treatment, diuretics were given, e.g.  
spironolactone 1 x 100 mg, furosemide 1 x 80 mg, and  
daily negative fluid balance of 500 cc.  
 The diagnosis of jaundice is established findings of  
yellowish eyes and body since 4 months before  
hospital admission, nausea, and alternating pruritus,  
lightening stools, darkening urine, and increased  
bilirubin level. Obstructive jaundice caused by  
cholelithiasis or tumor-induced bile obstruction was  
pondered. Examinations on a serial bilirubin test,  
urinalysis, and abdominal USG had been arranged.  
 The diagnosis of anemia was defined based on  
evident sign of pale conjunctiva with no bleeding signs.  
On admission, the patient’s hemoglobin level was  
8.2 g/dL, Mean Corpuscular Volume (MCV) 98.9 fL 
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and Mean Corpuscular Hemoglobine (MCH) 30.7 pg.  
Normocytic normochrome anemia due to occult blood  
loss was considered and it was also probably caused  
by chronic disease. Further tests were planned  
including reticulocyte count, serum irin (SI), Total Iron  
Binding Capacity (TIBC), ferritin, and serial  
peripheral blood test. Treatment was given based on  
underlying disease. There was no sign of heart failure  
due to anemia; therefore, blood transfusion could be 
on delay. The diagnosis of hypertension grade II is 
established based on history of hypertension and blood 
pressure data of 160/80 mmHg. Primary hypertension 
was considered with differential diagnosis of 
secondary hypertension. Treatment was provided, 
i.e. captopril 2 x 25 mg. 
The diagnosis of pneumonia was evident based on  
following signs: cough, fever, and leukocytocis  
11,600/uL and physical examination findings of coarse  
rhonchi at the left of lung base. The chest X-ray  
detected a minimum infiltrate in both lungs. Antibiotic  
treatment was given, e.g. cefotaxime 3 x 1 gram.  
Pulmonary tuberculosis as a differential diagnosis was  
considered and further sputum accumulation for acid  
fast test (AFT) 3x and the gram-staining test, as well  
as microorganism test and sputum culture were  
prepared. 
On the third-day of treatment, the patient’s  
condition was evaluated. The patient’s rhonchi had been  
progressively decreased and no more cough.  
The patient’s abdominal circumference was 77.5 cm,  
and body weight was 40 kg. Examinations of  
seromarker test on hepatitis HbsAg and anti HCV  
revealed negative result. Other laboratory result was  
as follow: hemoglobin 8 g/dL, leukocytes 10,500/uL,  
platelets 135,000/uL and Erythrocytes Sediment Rate  
(ESR) was 110 mm, and the differential count was  
within the normal limit. 
Reticulocyte count was 0% and the urinalysis 
revealed microscopic hematuria (erythrocytes 
15-20/hpf and Hb 2+) but no bilirubin was found. 
The result of cholinesterase test was 1,705 U/L (5,200- 
12,900). Serum bilirubin remained relatively the same 
as the previous result, i.e. direct bilirubin level of 
6.5 mg/dL and indirect 2.9 mg/dL. Serum iron test 
showed normal result of 96 ug/dL (60-160), TIBC of 
114 ug/dL (250-410) and ferritin level was 775.9 ng/ml 
(13-150). It represented anemia in chronic disease. 
Clinically, the patient still had jaundice. 
Based on USG result, there was an enlargement of  
intra-hepatic biliary system, splenomegaly, ascites and  
enlargement of gall bladder (11.1 x 5 cm), without any  
enlargement of paraaortic and parailliac lymph nodes  
(figure 1). 
Figure 1. Enlargement of intra-hepatic biliary system on abdominal 
ultrasonography 
At the eighth day care, total bilirubin increased into  
12 mg/dL, direct bilirubin was 8.9 mg/dL and indirect  
was 3.1 mg/dL, alkaline phosphatase test revealed  
increasing result, i.e. 941 U/L and gamma glutamyl- 
transpeptidase was 138 U/L, aminotransferase  
enzymes still increased, i.e. AST 198 U/L and ALT  
85 U/L. 
Based on the second result of abdominal USG, there  
was an impression of obstructive jaundice with  
suspect of a mass at the head of pancreas and  
differential diagnosis of cholangiocarcinoma. There  
was a feature of chronic liver disease (non- 
homogenous echostructure) and splenomegaly. 
The gall bladder was enlarged with a sludge feature, 
followed by enlargement of intrahepatic bile duct and 
Common Bile Duct (CBD). 
There was an increase of CEA, i.e. 6.2 
(0-4.6) ng/ml, and CA19 -9 of 228.1 (0-39) U/ml. 
Hemoglobin decreased to 6.7 g/dL, leukocytes 
11,200/uL, and platelets 169,000/uL, ESR 140 mm, 
reticulocyte count 3.6%, and normal differential count. 
Serum bilirubin decreased, i.e. direct bilirubin of 
4.8 mg/dL and indirect bilirubin of 2.4 mg/dL. 
There was inversed ratio of albumin 2.3 g/dL to  
globulin 5.5 g/dL. The serum iron was normal, i.e.  
62 ug/dL (60-160), TIBC revealed a result of  
145 ug/dL (250-410) and ferritin level was 466.7 ng/ml  
(13-150). Such results showed a fall compared to  
previous results. Decreased hemoglobin induced by  
bleeding has been considered; however, there was no  
bleeding sign, either in her stools or urine. On the 17th  
day of treatment, there were decreased of  
transaminase enzymes with AST 95 U/L and  
ALT 49 U/L. There was also a decrease of bilirubin,  
i.e. direct bilirubin of 3.39 mg/dL and indirect bilirubin  
of 1.6 mg/dL. 
On further day care, hemoglobin increased to 
7.8 g/dL, leukocytes 6,100/uL, and platelets 
186,000/uL. There was more decrease of serum  
bilirubin level, i.e. direct bilirubin of 3.43 mg/dL and  
indirect bilirubin of 0.63 mg/dL. The transaminase  
enzymes result included AST 97 U/L and ALT  
50 U/L. The renal function test was within the normal  
limit with ureum level of 36 mg/dL and creatinine level  
of 0.8 mg/dL.  
 
66 The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy 
 
 
 
 
Problems in Diagnosis Approach for Carcinoma  of Pancreatic Head 
Computer tommography (CT) scan of abdomen and 
pelvis showed an impression of a mass at the head of  
pancreas (attenuated after contrast), enlargement of  
pancreatic duct and intra-hepatic bile duct. There was  
an ascites in lower abdomen up to the pelvis with  
enlarged lien up to the Shufner 2. Based on CT scan  
result on pelvic region, there was an impression of  
ascites on pelvic region without definite enlargement  
of the left and right inguinal lymph node and intrapelvical  
mass (figure 2). 
 
 
 
 
 
 
 
 
 
There was no erythrocyte found on fecal  
specimen. Duodenoscopy was performed on this  
patient and revealed a normal form and measure of  
papilla vateri, and no mass was found. Based  
on  such  result,  an  Endoscopic  Retrograde  
Cholangiopancreatography (ERCP) was arranged.  
As preparation, a laboratory test was performed with  
result of hemoglobin 10.3 g/dL, leukocytes 5,200/uL,  
and platelets 140,000/u, Prothrombin Time (PT)  
1.03 x control, and Activated Partial Thromboplastin  
Time (APTT) 1.25 x control; direct bilirubin level was  
3.7 mg/dL and indirect bilirubin level was 1.3 mg/dL.  
The aminotransferase enzymes showed AST 114 U/L  
and ALT 76 U/L. The Ivy bleeding time 3 minutes, and  
Lee & White clotting time was 11 minutes.  
 ERCP result found a normal papilla vateri, normal  
multiple personality disorder (MPD), and no 
dilatation was found. The CBD was not able to be  
visualized because deep canulation can not be  
performed. Pancreatography showed dilatation of  
pancreatic duct due to the mass of pancreatic, which  
assumed as total mass obstruction. Afterward,  
the patient’s care was then arranged to be transferred  
to the division of digestive surgery for operation  
(figure 3 and 4). 
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DISCUSSION 
Pancreatic carcinoma together with carcinoma of  
duodenum, ampulla vater, distal common bile duct is  
categorized into the same group, i.e. the periampulla  
carcinoma because they are hard to be differ without  
evaluating specimen by resection (operation).  
The pancreatic carcinoma mostly occurs with  
prevalence of 50-70%, followed by ampulla carcinoma  
of 15-25%.3 The pancreatic carcinoma was 
predominantly located in the head of pancreas, i.e. about 
60-70%; while 5-10% occur in the body of pancreas 
and 10-15% in the tail. Approximately 15-40% cases 
are multifocal tumor. Histologically, most of 
pancreatic cancer is adenocarcinoma, with either 
moderate of good differentiation. 
Almost 85% patients have clinical symptoms of  
obstructive jaundice, pruritus, dark urine, lightening stool,  
and impression of obstructive bile duct (cholestatic) on  
liver function test. Symptoms of malignancy are  
associated with gradual onset, weight loss, and  
occasionally accompanied with abdominal pain and  
back pain. 
In general, pancreatic carcinoma occurs mostly on  
age 60-80 years. In this presented case, there is  
contradiction with epidemiologic evidence, i.e.  
the patient aged 54 years with symptoms of abdominal  
distension and jaundice. The history taking revealed  
symptoms of weight loss, intermittent abdominal pain,  
and jaundice. The pain was not classified as colic type;  
therefore it was not appropriate to gall stone disease.  
In addition, there was a weight loss presenting an  
initial symptom of malignancy. Some studies reported  
that 10-20% of pancreatic cancer is identified based  
on painless jaundice. Data of ascites, pretibial  
edema, inversed albumin-globulin ratio, and increased  
of transaminase enzymes leads to a diagnosis of liver  
cirrhosis. However, the examination of liver seromarker  
showed negative result. The cirrhosis in this patient  
probably indicates secondary bile cirrhosis due to  
obstruction in bile system. Bile obstruction may be  
caused by stone and tumor, particularly in the head of  
pancreas. Nevertheless, there were clinical  
manifestations that did not support the diagnosis of head  
pancreatic carcinoma, i.e. slight increase of bilirubin  
level, which spontaneously fall without any  
intervention. In pancreatic cancer, bilirubin level tends  
to increase when there is no intervention.  
Cholinesterase assay in the patient revealed  
a relatively low result indicating reduced liver function,  
particularly the function for synthesis. It may be caused  
by cirrhosis condition. 
The abdominal USG showed an impression of  
dilated intrahepatic bile system, splenomegaly, ascites,  
and an enlarged gall bladder (11.1 x 5 cm). The USG  
also revealed normal liver size with homogenous 
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structure. No stone was detected in the gall bladder 
and there was also no enlargement on para-aortic and  
parailiaca lymph nodes. The first USG examination has  
found no enlargement or a mass of pancreas and there  
was also no stone in the gall bladder. Such results can  
not explain the cause of dilated bile system and  
jaundice in the patient. On the other hand, the second  
abdominal USG showed an impression of obstructive  
jaundice which assumed due to the mass of pancreatic  
head, impression of chronic liver disease and  
splenomegaly. This explains that operator has very  
important role in USG examination. According to  
literatures, transabdominal USG can detect liver  
metastasis, ascites, and regional lymphadenopathy.  
The USG may also reveal dilatation of bile duct and  
may act as guidance for biopsy of pancreatic mass.  
However, the USG utilization is limited and it depends  
on the operator’s experiences, and some factors in  
the patients such as obesity and features of intestinal  
air. Therefore, USG is not reliable for diagnosing  
carcinoma of pancreatic head.3 
During hospitalization, there was increased  
bilirubin level which indicates an obstruction in bile  
system. If the condition persisted, then it required an  
intervention by stent application. However, along with  
the natural history of illness, the bilirubin level in this  
patient fell. Therefore, it becomes a rationale of  
discrepancy with carcinoma of pancreatic head, which  
usually has a stable or relatively increased serum  
bilirubin level. Diagnosis of malignancy in papilla vateri  
has been considered, which usually delicate that may  
have fluctuating bilirubin level. Other data that  
supports the diagnosis is the hemoglobin level which  
gradually decreased during hospitalization. Therefore,  
duodenoscopy examination to examine the papilla vateri  
has been taken into account. 
Increase CEA level (6.2 ng/ml), and CA19-9  
(228.1 U/ml) support the diagnosis of pancreas  
malignancy. There is no definite examination for  
tumor seromarker; however, CEA level > 3 ng/ml and  
CA19-9 > 37 U/ml shows 55 - 95% sensitivity. CEA is  
usually used for labeling neoplasm of duct, and  
negative result indicates normal pancreas. Positive  
result of CA19 - 9 occurs in 80% cases. Other test  
that can be performed is examination of protein  
kinase-C and mikroarray.4,5 
The hemoglobin decreased to 6.7 g/dL and followed  
by decreased serum bilirubin level in 2 days period.  
It is assumed that the decreased hemoglobin was  
caused by bleeding due to a fragile tumor. It may  
relatively cause bile drainage and hence explains  
the reason of decreased bilirubin level in the patient.  
Bleeding sign is not clear in the patient, but it can be  
demonstrated by occult blood test on fecal specimens.  
 The abdominal and pelvic CT scan demonstrated 
a mass on the head of pancreas, dilated pancreatic 
duct, and intrahepatic bile duct. There was ascites 
accompanied by enlarged lien up to Schufner II. 
The enlargement on the left and right side of inguinal 
lymph node was not clear because it was covered by 
ascites. The CT scan has a plus point in demonstrating 
parenchymal disorder or other abnormalities in duct. It 
can detect hypo and hyper-vascular mass, cysts, 
inflammation, and calcification. 
These are very helpful to find the pathological  
characteristic of pancreatic cancer. Three dimensional  
CT scan can also detect a smaller mass in more  
progressive nature. Its sensitivity to detect liver  
metastasis with diameter larger than 1.5 cm is almost  
100%.  CT  scan  can  diagnose  ascites  and  
lymphadenopathy, which act as a marker of regional  
metastasis. CT scan has 90% positive predictive value  
to determine which tumor that may not be able to be  
operated by evaluated the expanding mass into  
mesenteric vessels, particularly to superior mesenteric  
artery. There was no regional metastasis found in  
the patient. This has become prognostic factor in  
defining tumor resectibility.3 
The duodenoscopy test revealed normal papilla  
vateri. It excludes earlier suspicion as the differential  
diagnosis, i.e. carcinoma of papilla vateri. Subsequently,  
for definite diagnosis, ERCP test was further arranged.  
ERCP is a diagnostic test to provide a direct  
visualization on pancreatic and bile ductal by injecting  
a contrast solution. ERCP may also enable us to  
perform tissue biopsy on the abnormal site. However,  
the role of ERCP in determining pre-operative staging  
is limited because it is unable to determine  
the metastasis in the liver and lymph node as well as  
vascular invasion. ERCP is useful in intervention  
treatment such as stone extraction and stent  
application.3 
Another test which is comparable to ERCP is  
Magnetic Resonance Cholangio Pancreatography  
(MRCP).  This  test  has  more  non-invasive  
characteristic compared to ERCP. The Magnetic  
Resonance Imaging (MRI) provides a cross-sectional  
image of parenchyma, bile duct and pancreas duct.  
It is also able to differentiate benign mass from  
malignancy with 95% accuracy in predicting  
the respectability. The MRCP shows an image as ERCP  
does without any complication due to contrast  
injection into the pancreatic duct; therefore, it can be  
used in patients who are allergic patient to contrast or  
for patients with renal function disorder. MRCP  
sensitivity is about 84% compared to ERCP which has  
70% sensitivity; and the specificity is 97% compared  
to 94% in detecting pancreatic cancer.6  
 According to a study by Kaltenthaler et al, MRCP  
is comparable to ERCP in detecting bile obstruction  
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with 50-100% sensitivity and 83-100% specificity. 
It has sensitivity of 81-94% and specificity of 92-100%  
in detecting malignancy.7 The MRCP is more superior  
to ERCP for detecting total obstruction of pancreatic  
duct. However, this advantage will be ineffective when  
therapeutic intervention is required. ERCP is still the  
procedure of choice for the patient who is contra- 
indicated to MRCP and requiring therapeutic  
procedures.8 
MRCP sensitivity and specificity in detecting  
malignancy are 81% and 100%, respectively, which is  
comparable to ERCP, i.e. 93% and 94%. MRCP may  
prevent unnecessary invasive exploration on  
the common bile duct and pancreatic duct.9 MRCP  
provides useful staging data for the patient.  
Georgopoulos et al, reported that the result of MRCP  
was found in line with operative findings, either on size,  
location, or related involvement of mesenteric vessel.  
Moreover, MRCP also provides data of disease  
distribution, which can not be performed by single ERCP  
examination.10 
The role of ultrasonograph endoscopy as 
diagnostic test includes demonstrating the parenchyma 
of pancreas, common bile duct, duodenum and 
ampulla. It can detect a mass sized less than 2 
cm. Furthermore, it may also detect the depth of 
mass invasion with 95% sensitivity, but the specificity is 
only 53% because it is not quite able to differentiate 
malignancy from chronic pancreatitis. 
Positron Emission Tomography (PET) scan is a 
modality that may be helpful in diagnosing periampulla 
neoplasm through altering the function of pancreas 
cancer cells by using radionucleotide rather than 
evaluating abnormal structure. It can distinguish 
neoplasm and chronic pancreatitis with 85-98% 
sensitivity and 53-93% specificity.3 
The prognosis of pancreatic cancer depends on  
some factors. Tumor with poor differentiation has the  
worst prognosis. Tumor located in the body or tail of  
pancreas usually has reached more advanced stage.  
Tumor size also determines the prognosis, particularly  
if it is > 3 cm. Tumor metastasis usually depends on  
the fat tissue of peripancreatic retroperitoneum, nerves,  
blood vessels, and lymph vessel. Lymph nodes which  
are usually involved are superior and posterior  
pancreaticoduodenal. The most common distant  
metastasis is in the liver and peritoneum, and other  
organs including lung, bone, kidney, brain and skin.  
 The 2-year survival rate for pancreatic cancer is  
28%; while the 5-year survival rate is about 3.5-12%.  
In the untreated patients, the survival rate is about  
3 months, and when the radical resection was  
performed, the survival rate will increase up to  
10-20 months. 
The treatment choice for pancreatic cancer includes  
surgical resection, but only 10-20% cases are selected 
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as candidates for operation. Chemotherapy only brings 
10% response with moderate toxic chemotherapy 
effect.11 Radiotherapy is usually not effective for 
pancreatic carcinoma treatment. 
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